New hope for melanoma: drug cocktail battle for BRAF patients after first treatment fails
NCT ID NCT05926960
First seen Jan 08, 2026 · Last updated May 15, 2026 · Updated 19 times
Summary
This study compares two combinations of drugs for people with advanced melanoma that has a specific genetic change (BRAF V600E/K) and has worsened after prior anti-PD-1 therapy. Participants receive either a three-drug combo (encorafenib, binimetinib, and pembrolizumab) or a two-drug combo (nivolumab and ipilimumab). The goal is to see which combination works better at shrinking tumors and controlling the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
A.O.U. Policlinico Paolo Giaccone
Palermo, Sicily, 90127, Italy
-
AO Santa Maria della Misericordia
Perugia, Umbria, 06132, Italy
-
Azienda Ospedaliero Universitaria Senese
Siena, Tuscany, 53100, Italy
-
Fachklinik Hornheide
Münster, North Rhine-Westphalia, 48157, Germany
-
Hospital General Universitario Gregorio Marañon
Madrid, 28007, Spain
-
Hospital General Universitario de Valencia
Valencia, Valenciana, Comunitat, 46014, Spain
-
Hospital Germans Trias i Pujol
Badalona, Barcelona [barcelona], 08916, Spain
-
Hospital Universitari Vall d'Hebron
Barcelona, Barcelona [barcelona], 08035, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario Miguel Servet
Zaragoza, 50009, Spain
-
Institut Català d'Oncologia - L'Hospitalet
L'Hospitalet de Llobregat, Catalunya [cataluña], 08908, Spain
-
Istituto Europeo di Oncologia IRCCS
Milan, 20141, Italy
-
Istituto Nazionale Tumori IRCCS Fondazione Pascale
Naples, 80131, Italy
-
Istituto Nazionale Tumori Regina Elena
Rome, ROMA, 00144, Italy
-
Istituto Oncologico Veneto IRCCS
Padova, Veneto, 35128, Italy
-
Istituto di Candiolo IRCCS - Fondazione del Piemonte per l'Oncologia
Candiolo, Torino, 10060, Italy
-
Medizinische Hochschule Hannover
Hanover, Lower Saxony, 30625, Germany
-
Narodny onkologicky ustav
Bratislava, 833 10, Slovakia
-
Neovizia, s.r.o.
Bratislava, 85101, Slovakia
-
Pratia MCM Krakow
Krakow, 30-727, Poland
-
Universitaetsklinikum Essen
Essen, North Rhine-Westphalia, 45147, Germany
-
Universitaetsklinikum Tuebingen
Tübingen, Baden-Wurttemberg, 72076, Germany
-
Universitätsklinikum Schleswig-Holstein
Lübeck, Schleswig-Holstein, 23538, Germany
-
Universitätsmedizin Johannes Gutenberg Universität Mainz
Mainz, Rhineland-Palatinate, 55131, Germany
Conditions
Explore the condition pages connected to this study.